tm
Seeing Is Believing
tm
Seeing Is Believing
Currently out of the existing stock ratings of Michael Ulz, 81 are a BUY (62.79%), 45 are a HOLD (34.88%), 3 are a SELL (2.33%).
Analyst Michael Ulz works at MORGAN STANLEY with a stock forecast success ratio of 55.85% fulfilled within 173.91 days on average.
Michael Ulz’s has documented 287 price targets and ratings displayed on 33 stocks. The coverage is on the Healthcare sector.
Most recent stock forecast was given on FATE, Fate Therapeutics at 27-Feb-2024.
Analyst best performing recommendations are on NRIX (NURIX THERAPEUTICS ).
The best stock recommendation documented was for AKRO (AKERO THERAPEUTICS) at 12/19/2022. The price target of $40 was fulfilled within 1 day with a profit of $1.22 (3.15%) receiving and performance score of 31.46.
Average potential price target upside
Analyst name
Rating
Current price target
Potential distance
Previous price target
Date
Price targets met ratio
Average potential upside
Average Time (Days) For PT To Be Met
Performance score
Buy
205
$22.5 (12.33%)
2 years 11 months 13 days ago
3/5 (60%)
$35.09 (20.65%)
938
Hold
173
$-9.5 (-5.21%)
156
2 years 11 months 15 days ago
14/24 (58.33%)
$2.73 (1.60%)
682
Hold
190
$7.5 (4.11%)
194
3 years 2 months 14 days ago
9/11 (81.82%)
$34.41 (22.12%)
350
Hold
166
$-16.5 (-9.04%)
175
3 years 2 months 14 days ago
23/23 (100%)
$10.41 (6.69%)
828
Buy
155
3 years 3 months 11 days ago
7/7 (100%)
$36.79 (31.12%)
395
Which stock is Michael Ulz is most bullish on?
Which stock is Michael Ulz is most reserved on?
What Year was the first public recommendation made by Michael Ulz?
